Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 30
Retatrutide: a plain-English explainer
Retatrutide is an investigational triple-receptor agonist: GLP-1, GIP, and glucagon. Phase 2 data showed up to 24% weight loss at 48 weeks. Not approved.
Semaglutide doses in published trials
Dose regimens from the STEP, SUSTAIN, and SELECT trials. All figures come from published protocols, not from prescribing guidance.
Semaglutide P29: a new production method
A 2026 PLoS ONE study reports 5.85 g/L yield and 98% purity for the semaglutide main-chain intermediate using a SNAC-tagged bacterial expression system.
Semaglutide and diabetes recovery stories
A 2026 medical humanities paper asks what happens to patient recovery narratives when semaglutide does much of the biological work.
Semaglutide and weight in schizophrenia
A 24-week trial found semaglutide reduced body weight by 9.8% in people with schizophrenia on clozapine or olanzapine, with partial regain after stopping.
Thymosin β4 limits sepsis damage in mice
A May 2026 Biomolecules study found recombinant thymosin beta-4 cut lung injury and brain inflammation in septic mice, with 80% survival at 72 hours.
GLP-1 drugs and mental health: a 2026 study
A June 2026 cohort study found lower rates of anxiety and depression in adults on tirzepatide or semaglutide vs other weight-loss drugs, and what that means.
Tirzepatide and steatotic liver disease
A 2026 real-world study finds tirzepatide cut major liver complications and mortality in adults with steatotic liver disease and cardiometabolic dysfunction.
Tirzepatide vial crystals: what they mean
A tirzepatide vial with residue or cloudiness fails the licensed product's visual standard. Here is what the physical changes signal and what to do.
GLP-1/GIPR/FGF21 peptibody in DIO mice
A preclinical peptibody hitting GLP-1, GIPR, and FGF21 reduced body weight and improved metabolic markers in obese mice. Human translation is unknown.
Ipamorelin history: discovery to today
Ipamorelin was first characterised at Novo Nordisk in 1998. Here is the research timeline and why no approved medicine followed.
How ipamorelin works: mechanism explained
Ipamorelin binds the GHS-R1a receptor to trigger a selective growth-hormone pulse without raising cortisol or prolactin.